ライフサイエンスコーパス: sustained virologic response

1 cations of sepsis 4 months after achieving a sustained virologic response.

2 f the 31 patients treated, 30 (97%) achieved sustained virologic response.

3 atients during treatment and after achieving sustained virologic response.

4 baseline resistance polymorphisms achieved a sustained virologic response.

5 ctable HCV RNA by Abbott RealTime achieved a sustained virologic response.

6 the month following enrollment and achieving sustained virologic response.

7 of the 116 patients receiving placebo had a sustained virologic response.

8 ents and ribavirin resulted in high rates of sustained virologic response.

9 treatment course, and 61 (50%) have achieved sustained virologic response.

10 as associated with a greater likelihood of a sustained virologic response.

11 All 30 recipients achieved a sustained virologic response.

12 notype 3 infection resulted in high rates of sustained virologic response.

13 ng to adverse events after week 18 but had a sustained virologic response.

14 herapy, n=3; IFN/ribavirin, n=11); all had a sustained virologic response.

15 apy (DAAs) therapy for HCV despite achieving sustained virologic response.

16 pe 3 containing this variant reduces odds of sustained virologic response.

17 tion in HCC risk over time after DAA-induced sustained virologic response.

18 highest-risk group for HCC after DAA-induced sustained virologic response.

19 nt even in patients that ultimately attain a sustained virologic response.

20 dverse events; three of these patients had a sustained virologic response.

21 All patients achieved sustained virologic response.

22 Of the 13 patients who did not have a sustained virologic response, 10 had a relapse after the

23 Primary endpoint was sustained virologic response 12 weeks after end of treat

24 otype (GT)1-infected patients, high rates of sustained virologic response 12 weeks after planned end

25 icantly superior to placebo and PR; rates of sustained virologic response 12 weeks after planned end

26 The primary end point was a sustained virologic response 12 weeks after the completi

27 The sustained virologic response 12 weeks after the completi

28 nts (100%) achieved the primary outcome of a sustained virologic response 12 weeks after the date of

29 The primary end point was the rate of sustained virologic response 12 weeks after the end of s

30 04 patients had detectable HCV RNA following sustained virologic response 12 weeks after the end of t

31 nce of late recurrent viremia (patients with sustained virologic response 12 weeks after the end of t

32 Eight of 9 (89%) achieved sustained virologic response 12 weeks after the end of t

33 The primary efficacy endpoint was sustained virologic response 12 weeks after the end of t

34 The primary endpoint was sustained virologic response 12 weeks after the end of t

35 The primary endpoint was sustained virologic response 12 weeks after the end of t

36 The primary efficacy end point was a sustained virologic response 12 weeks after the end of t

37 The primary end point was a sustained virologic response 12 weeks after the end of t

38 The primary efficacy end point was sustained virologic response 12 weeks after therapy (SVR

39 The primary efficacy endpoint was sustained virologic response 12 weeks after therapy (SVR

40 vestigated whether patients who maintained a sustained virologic response 12 weeks after therapy (SVR

41 The primary end point was sustained virologic response 12 weeks after treatment (S

42 lyzed to assess completion of treatments and sustained virologic response 12 weeks after treatment (S

43 Sustained virologic response 12 weeks after treatment (S

44 dpoint was the percentage of patients with a sustained virologic response 12 weeks after treatment (S

45 The primary endpoint was sustained virologic response 12 weeks after treatment (S

46 = 564; CTP class B/C, n = 175), 90% achieved sustained virologic response 12 weeks after treatment (S

47 ithout ribavirin, demonstrated high rates of sustained virologic response 12 weeks after treatment en

48 ibitor, 16 weeks treatment with G/P produced sustained virologic response 12 weeks after treatment in

49 Proportions of patients with sustained virologic response 12 weeks after treatment in

50 Sustained virologic response 12 weeks after treatment wa

51 The primary end point was sustained virologic response 12 weeks after treatment.

52 The primary end point was a sustained virologic response 12 weeks after treatment.

53 Sustained virologic response 12 weeks post-treatment (SV

54 observational study to determine real-world sustained virologic responses 12 weeks after treatment (

55 A higher percentage of patients achieved a sustained virologic response 24 weeks after therapy ende

56 We report the rate of sustained virologic response 24 weeks after therapy.

57 us sofosbuvir for HCV infection, the rate of sustained virologic response across all genotypes was 97

58 Rates of sustained virologic response across all genotypes were 9

59 The rates of sustained virologic response across all treatment subgro

60 ts with chronic HCV infection who achieved a sustained virologic response after 12 weeks of treatment

61 for 24 weeks in patients who did not achieve sustained virologic response after prior treatment with

62 h residual HCV-RNA in the explant achieved a sustained virologic response after receiving their liver

63 Sustained virologic response after treatment among HCV-i

64 fected with HCV genotype 1 who had not had a sustained virologic response after treatment with pegint

65 epatitis C virus (HCV) and who do not have a sustained virologic response after treatment with regime

66 patasvir for 12 weeks provided high rates of sustained virologic response among both previously treat

67 of serious adverse events and a high rate of sustained virologic response among liver-transplant reci

68 ir taken for 12 weeks provided high rates of sustained virologic response among patients across HCV g

69 sofosbuvir was associated with high rates of sustained virologic response among patients infected wit

70 The rate of sustained virologic response among patients receiving so

71 vir and sofosbuvir resulted in high rates of sustained virologic response among patients with HCV gen

72 The study regimen resulted in high rates of sustained virologic response among patients with HCV gen

73 r 8 weeks was associated with a high rate of sustained virologic response among previously untreated

74 hibitor ledipasvir resulted in high rates of sustained virologic response among previously untreated

75 ribavirin was associated with high rates of sustained virologic response among previously untreated

76 tect any significant differences in rates of sustained virologic response among the three study group

77 The primary efficacy end point was a sustained virologic response (an HCV RNA level of <25 IU

78 The primary end point was a sustained virologic response (an HCV RNA level of <25 IU

79 Ninety-three percent achieved a sustained virologic response and DAA therapy was well to

80 ologic response (CVR) included pretransplant sustained virologic response and post-transplant virolog

81 Primary endpoints included sustained virologic response as defined as negative vira

82 d dasabuvir plus ribavirin, concordance of a sustained virologic response at 12 and 24 weeks supports

83 Failed DAA/PR Therapy) demonstrated a 96.2% sustained virologic response at 12 weeks (SVR12) rate us

84 Sustained virologic response at 12 weeks (SVR12).

85 </=15 IU/mL 12 weeks after stopping therapy (sustained virologic response at 12 weeks [SVR12]).

86 s than 25 IU/mL at 12 weeks after treatment (sustained virologic response at 12 weeks [SVR12]).

87 The primary outcome was a composite of a sustained virologic response at 12 weeks after completio

88 us while on therapy and 100% have achieved a sustained virologic response at 12 weeks after completio

89 int was the proportion of patients achieving sustained virologic response at 12 weeks after the cessa

90 The primary endpoint was sustained virologic response at 12 weeks after the end o

91 e primary end point for the two trials was a sustained virologic response at 12 weeks after the end o

92 The primary end point was sustained virologic response at 12 weeks after the end o

93 The primary end point was a sustained virologic response at 12 weeks after the end o

94 Overall, 322 patients (96%) had a sustained virologic response at 12 weeks after the end o

95 The primary end point was sustained virologic response at 12 weeks after the end o

96 The primary end point was sustained virologic response at 12 weeks after the end o

97 the two studies, the primary end point was a sustained virologic response at 12 weeks after the end o

98 The primary endpoint was sustained virologic response at 12 weeks after the end o

99 The primary efficacy end point was sustained virologic response at 12 weeks after therapy (

100 Measurements: The primary end point was sustained virologic response at 12 weeks after therapy e

101 The primary end point was sustained virologic response at 12 weeks after therapy e

102 The primary endpoint was sustained virologic response at 12 weeks posttreatment (

103 dpoint was the percentage of patients with a sustained virologic response at 12 weeks posttreatment.

104 Per protocol rates of sustained virologic response at 12 weeks were 98.1% (622

105 The 2 patients who did not achieve sustained virologic response at 12 weeks were lost to fo

106 fidence interval, 82%-97%) patients achieved sustained virologic response at 12 weeks, including 36 o

107 dence interval 93%-100%) of patients reached sustained virologic response at 12 weeks.

108 The primary end point was sustained virologic response at 24 weeks after the end o

109 mg of ritonavir) plus ribavirin, the rate of sustained virologic response at 24 weeks after treatment

110 eron alfa-2a and ribavirin for 8 weeks had a sustained virologic response at 24 weeks, as did 6 of 10

111 no response to previous therapy (10%) had a sustained virologic response at 24 weeks.

112 s and interferon for 4, 8, or 12 weeks had a sustained virologic response at 24 weeks.

113 in in 12 centers across Thailand to estimate sustained virologic response at post-treatment week 12 (

114 530 (NS5A inhibitor) has shown high rates of sustained virologic response at post-treatment week 12 (

115 ectives were to evaluate safety, the rate of sustained virologic response at post-treatment week 12 (

116 nts who received 24 weeks of treatment had a sustained virologic response at post-treatment week 12,

117 nts who received 12 weeks of treatment had a sustained virologic response at post-treatment week 12,

118 ive-regimen group, 286 of 297 patients had a sustained virologic response at post-treatment week 12,

119 Of the 34 study participants, 33 had a sustained virologic response at post-treatment weeks 12

120 The primary efficacy measure was sustained virologic response at posttreatment week 12 (S

121 Sustained virologic response at posttreatment week 12 (S

122 endpoint was the percentage of patients with sustained virologic response at posttreatment week 12 (S

123 By intent-to-treat analysis, sustained virologic response at posttreatment week 12 wa

124 ed in primary care had a noninferior rate of sustained virologic response at Week 12 (SVR12), compare

125 The primary end point was a sustained virologic response at week 12 after the end of

126 response with HCV protease inhibitors had a sustained virologic response at week 12 after the end of

127 One hundred percent of patients exhibited sustained virologic response at week 12 after the end of

128 Proportion of patients with sustained virologic response at week 12 after treatment

129 High rates of sustained virologic response at week 12 were observed am

130 18 patients with genotype 3 infection had a sustained virologic response at week 12.

131 are at release" model increased the lifetime sustained virologic response by 23%, reduced cirrhosis c

132 ents with V at position 150, 71% achieved an sustained virologic response compared to 88% with A at p

133 r treatment durations and increased rates of sustained virologic response compared with existing ther

134 A sustained virologic response, defined as an undetectable

135 Rates of sustained virologic response did not differ by receipt o

136 with a DAA regimen and patients who achieved sustained virologic responses had the lowest risk for CV

137 Reinfection after sustained virologic response has been reported, but is t

138 I, 0.18-0.47), but not in patients without a sustained virologic response (hazard ratio, 1.13; 95% CI

139 sessment was the proportion of patients with sustained virologic response (HCV RNA <25 IU/mL) at post

140 The primary efficacy endpoint was sustained virologic response (HCV RNA below the limit of

141 .37-6.05) but lower among those who attained sustained virologic response (HR, .52; 95% CI, .42-.63).

142 t ribavirin has shown efficacy in inducing a sustained virologic response in a phase 2 study involvin

143 tivariate analysis on their association with sustained virologic response in a separate cohort of 411

144 l-oral HCV regimens have shown high rates of sustained virologic response in both clinical trials and

145 The rate of sustained virologic response in each group was compared

146 The rate of sustained virologic response in group A was 96.2% (95% c

147 red direct-acting agents to achieve complete sustained virologic response in humans.

148 ost potent direct-acting agents with durable sustained virologic response in humans.

149 ibitor velpatasvir resulted in high rates of sustained virologic response in patients chronically inf

150 fosbuvir for 12 weeks provided high rates of sustained virologic response in patients coinfected with

151 ived antiviral therapy, with higher rates of sustained virologic response in patients with genotype 2

152 asvir for 24 weeks resulted in high rates of sustained virologic response in patients with HCV infect

153 svir for 12 weeks resulted in a high rate of sustained virologic response in patients with stage 4 or

154 As compared with the rate of sustained virologic response in the group that received

155 ng patients with HCV genotype 2, the rate of sustained virologic response in the sofosbuvir-velpatasv

156 ng patients with HCV genotype 3, the rate of sustained virologic response in the sofosbuvir-velpatasv

157 uvir plus ledipasvir for 12 weeks achieved a sustained virologic response, including 7 with advanced

158 edian time of 12 weeks of therapy; all had a sustained virologic response (no detectable serum HCV RN

159 Among 282 subjects who did not achieve sustained virologic response, no novel sofosbuvir resist

160 Sustained virologic response occurred in 74% (28 in 38)

161 al load 24 weeks after treatment completion (sustained virologic response of 24 weeks [SVR24]).

162 genotype 1 or 4 HCV infection had a rate of sustained virologic response of 90% at 12 weeks.

163 psychiatric diseases do not differ regarding sustained virologic response or IFN-alpha-associated com

164 notherapy, combination therapy had a greater sustained virologic response rate (64% vs. 33%; relative

165 The overall sustained virologic response rate 12 weeks after the end

166 The sustained virologic response rate among those with compl

167 Sustained virologic response rate and adverse event-rela

168 The sustained virologic response rate was 98% (102 of 104 pa

169 highest risk of advanced fibrosis and lowest sustained virologic response rate.

170 Empirical cross-trial data indicated high sustained virologic response rates (>90%) in prior relap

171 ral agents have revolutionized therapy, with sustained virologic response rates (undetectable viral l

172 patitis C viral protease inhibitors increase sustained virologic response rates compared to interfero

173 ct-acting antiviral regimens that offer high sustained virologic response rates even in the setting o

174 Although some studies have suggested higher sustained virologic response rates in HCV-infected women

175 improved outcomes for coinfected patients as sustained virologic response rates now exceed 95% and fi

176 With or without concomitant antiretrovirals, sustained virologic response rates were higher in patien

177 The primary end point was sustained virologic response (serum HCV RNA <25 IU/mL) 1

178 In the sustained virologic response (SVR) (36) and spontaneousl

179 Those who achieved sustained virologic response (SVR) (n = 141; 94%) were e

180 If this cohort had a 90% rate of sustained virologic response (SVR) 4 weeks after treatme

181 s C virus (HCV) infection have high rates of sustained virologic response (SVR) after 12 weeks of tre

182 Sustained virologic response (SVR) after direct acting a

183 Achievement of a sustained virologic response (SVR) after treatment for H

184 ere 13.3 (95% CI 12.2-14.5) for those with a sustained virologic response (SVR) and 19.2 (95% CI 17.4

185 rapy associated with increased likelihood of sustained virologic response (SVR) and an association be

186 ese anemia management strategies on rates of sustained virologic response (SVR) and safety.

187 Rates of sustained virologic response (SVR) at 12 weeks were avai

188 Pre-treatment predictors of sustained virologic response (SVR) at 24 weeks following

189 act of psychoeducation (PE) on retention and sustained virologic response (SVR) during HCV therapy am

190 nation of antiviral treatment, patients with sustained virologic response (SVR) had improved signific

191 s recommend continued HCC surveillance after sustained virologic response (SVR) has been achieved.

192 l models of care for promoting adherence and sustained virologic response (SVR) have not been evaluat

193 Antiviral treatment with sustained virologic response (SVR) improves survival in

194 s (HCV) genotype 2 or 3 infection produces a sustained virologic response (SVR) in 70%-80% of patient

195 is (ALF) in CHC treatment-naive patients and sustained virologic response (SVR) in CHC patients on pe

196 We evaluated the benefit of sustained virologic response (SVR) in patients with HCV

197 alpha (IFN-alpha) and ribavirin can induce a sustained virologic response (SVR) in some but not all h

198 atment from 2000 through 2015 and achieved a sustained virologic response (SVR) in the Veterans Healt

199 svir, and dasabuvir to produce high rates of sustained virologic response (SVR) in these patients.

200 The sustained virologic response (SVR) in treatment-naive pa

201 Multivariate models of sustained virologic response (SVR) included age, race, c

202 the Cochrane Group remains unconvinced that sustained virologic response (SVR) is a validated surrog

203 human immunodeficiency virus (HIV) in whom a sustained virologic response (SVR) is achieved.

204 , compared to the study-defined, historical, sustained virologic response (SVR) of 60% with pegylated

205 The aim of this study was to assess sustained virologic response (SVR) of LDV/SOF+/-ribaviri

206 The impact of sustained virologic response (SVR) on mortality after di

207 ed pegylated IFN plus ribavirin therapy with sustained virologic response (SVR) or nonresponse (NR) w

208 al blood from patients who achieved either a sustained virologic response (SVR) or relapsed.

209 (RBV) significantly increases the chances of sustained virologic response (SVR) over treatment with P

210 Six DAA regimens showed high sustained virologic response (SVR) rates (>95%) in patie

211 ibavirin (RBV) for 12 weeks resulted in high sustained virologic response (SVR) rates along with mini

212 High sustained virologic response (SVR) rates have been obser

213 f the literature on treatment completion and sustained virologic response (SVR) rates in DUs.

214 Sustained virologic response (SVR) rates measured 24 wee

215 plus ribavirin for 24 weeks, which leads to sustained virologic response (SVR) rates of 65%-80%.

216 cting antivirals (DAAs) for 6 weeks achieves sustained virologic response (SVR) rates of 95% in some

217 and ribavirin (RBV) significantly increases sustained virologic response (SVR) rates over PegIFN/RBV

218 SOF/RBV costs approximately US$169,000, with sustained virologic response (SVR) rates ranging from 52

219 Sustained virologic response (SVR) rates were 56%, 72%,

220 Sustained virologic response (SVR) rates with pegylated

221 Long-term changes after sustained virologic response (SVR) remain unknown.

222 rapy, patients with POAE had a lower rate of sustained virologic response (SVR) than those without PO

223 Sustained virologic response (SVR) to interferon (IFN)-f

224 thnicity were associated with lower rates of sustained virologic response (SVR) to interferon-based t

225 baseline HOMA-IR and pretreatment factors on sustained virologic response (SVR) to telaprevir (TVR) i

226 Of 48 patients who completed therapy, sustained virologic response (SVR) was achieved in 43 (8

227 Sustained virologic response (SVR) was not achieved in 9

228 ce interval [CI], .33-.57) and attainment of sustained virologic response (SVR) were associated with

229 The aim of this review was to investigate sustained virologic response (SVR), adherence, discontin

230 completed treatment, 8.7% were assessed for sustained virologic response (SVR), and 8.0% achieved SV

231 The primary end point was sustained virologic response (SVR), and secondary end po

232 orter treatment duration and higher rates of sustained virologic response (SVR), and the role of HCV

233 nd ribavirin therapy are likely to achieve a sustained virologic response (SVR), and we hypothesized

234 Among 31 subjects with sustained virologic response (SVR), anti-HCV became unde

235 The primary outcome was sustained virologic response (SVR), defined as the level

236 2010 to March 2018) was conducted to assess sustained virologic response (SVR), discontinuation rate

237 ral agents are associated with high rates of sustained virologic response (SVR), generally exceeding

238 d glucose were minimal and did not differ by sustained virologic response (SVR), HIV, diabetes, or fi

239 l (DAA) therapies are effective in achieving sustained virologic response (SVR), however, whether suc

240 for complete early virologic response (EVR), sustained virologic response (SVR), relapse, treatment d

241 8-24 weeks is associated with high rates of sustained virologic response (SVR).

242 nd SOF-based therapies lead to high rates of sustained virologic response (SVR).

243 therapy for HCV, of whom 106 (45%) achieved sustained virologic response (SVR).

244 ation and different doses of ALV plus RBV on sustained virologic response (SVR).

245 Similar results were found for sustained virologic response (SVR).

246 The primary end point was sustained virologic response (SVR).

247 t and 13 (59%) of treated persons achieved a sustained virologic response (SVR).

248 ant variants in patients who did not achieve sustained virologic response (SVR).

249 c and extrahepatic benefits of a DAA-induced sustained virologic response (SVR).

250 direct-acting antiviral (DAA) treatment, and sustained virologic response (SVR).

251 levels obtained pre-HCV treatment and after sustained virologic response (SVR).

252 atment with DAA, and 29,090 (19.4%) achieved sustained virologic response (SVR).

253 d treatment, and 119 (91% of initiators) had sustained virologic response (SVR).

254 ng antivirals, and 29 090 (19.4%) achieved a sustained virologic response (SVR).

255 kinetics of the host response could predict sustained virologic response (SVR).

256 lations at greater risk of reinfection after sustained virologic response (SVR).

257 The primary efficacy endpoint was sustained virologic response (SVR; HCV RNA <15 IU/mL aft

258 nd point was the proportion of patients with sustained virologic response (SVR; undetectable HCV RNA)

259 feron and ribavirin yields approximately 40% sustained virologic responses (SVR).

260 titis C virus (HCV) at week 24 of follow-up (sustained virologic response [SVR] 24) as a primary end

261 tudy sample comprised 903 patients (328 with sustained virologic response [SVR]).

262 untreated HCV RNA positive, 345 treated with sustained virologic response [SVR], 43 during treatment,

263 nt (EOT) liver biopsies from 8 patients (n=7 sustained virologic response [SVR]; n=1 relapse) and unp

264 HCV RNA levels at end of treatment (EOT) for sustained virologic response (SVR12) during interferon-s

265 use during therapy on completion, adherence, sustained virologic response (SVR12), and safety of ledi

266 n, OST did not impact completion, adherence, sustained virologic response (SVR12), or safety.

267 of follow-up or thereafter was assumed as a sustained virologic response (SVR12).

268 A <15 IU/mL 12 weeks after stopping therapy (sustained virologic response [SVR12]).

269 apse occurred in the W28 arm, resulting in a sustained virologic response (SVR12TND) rate of 100% (12

270 L trends in HCV patients who did not achieve sustained virologic responses (SVRs) after treatment wit

271 sofosbuvir-velpatasvir resulted in rates of sustained virologic response that were superior to those

272 residual risk for disease progression after sustained virologic response, the optimal approach to cu

273 rhosis, 20 started treatment, and 9 achieved sustained virologic response thus far.

274 ; risk of death was reduced in patients with sustained virologic response to DAA therapy (hazard rati

275 This association differed by sustained virologic response to DAA therapy; risk of dea

276 e 1 infection in patients who have not had a sustained virologic response to prior interferon-based t

277 h HCV genotype 1 infection who had not had a sustained virologic response to prior interferon-based t

278 ent groups and in patients with vs without a sustained virologic response to therapy.

279 hanges in clonal B cells of MC patients with sustained virologic responses to direct-acting antiviral

280 Key outcomes included sustained virologic response (undetectable HCV RNA 12 we

281 V) infection have demonstrated high rates of sustained virologic response, virologic failure may stil

282 ginterferon was not an option, the rate of a sustained virologic response was 78% (95% confidence int

283 The rate of sustained virologic response was 94% (95% confidence int

284 In POLARIS-1, the rate of sustained virologic response was 96% with sofosbuvir-vel

285 A sustained virologic response was also observed in 4 pati

286 A sustained virologic response was associated with a lower

287 Sustained virologic response was documented for 10 of 17

288 Sustained virologic response was high in nonadherent (89

289 The criterion for a sustained virologic response was met in 68 of 73 patient

290 In the single-group study, a sustained virologic response was reported in 90% of pati

291 Among patients with genotype 1, a sustained virologic response was reported in 96.4% (95%

292 Overall rates of sustained virologic response were 83% (95% confidence in

293 The rates of sustained virologic response were 99% (95% confidence in

294 The rates of sustained virologic response were high in all treatment

295 High rates of sustained virologic response were observed among patient

296 Rates of sustained virologic response were similar regardless of

297 At 24 weeks after the end of therapy, sustained virologic responses were achieved in 89%, 93%,

298 ll but statistically significant decrease in sustained virologic response with DAA therapy.

299 ts and 98% of 41 patients who did not have a sustained virologic response with HCV protease inhibitor

300 eiving 24-week total therapy, 87% achieved a sustained virologic response with undetectable HCV RNA b